The Trump administration would need to finalize the proposed Medicare and Medicaid rule before it would take effect.

In one of the Biden administration’s final health policy pushes, the White House unveiled a proposal to ensure Medicare and ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to increase oversight of the Medicare Advantage and prescription drug programs for contract year 2026.

The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and ...

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs ...

The proposed rule could give millions of Americans access to the new drugs; it will also put pressure on the incoming Trump administration.

CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

A row is brewing between the White House and Robert F Kennedy Jr after the Biden administration proposed making millions of ...

The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and $11 billion for Medicaid over a decade. Total Medicare drug spending over ...